Bristol Myers Squibb

News

EU regulators back BMS' Opdivo in new skin cancer use

Bristol-Myers Squibb’s cancer immunotherapy Opdivo is likely to gain another use in Europe after regulators recommended it after surgery for skin cancer.

Event coverage

ASCO 2018 - Monday 4th June: BMS tries different tack as Mer...

Merck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow of data from its Keytruda checkpoint inhibitor drug at the conference in Chi

Views & Analysis

ASCO 2018 - Sunday 3rd June: Opdivo/Nektar, AbbVie's new leu...

Bristol-Myers Squibb is hoping to revive its Opdivo cancer immunotherapy by combining it with an experimental agent from Nektar Therapeutics. But new early stage data from the cocktail pres

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

Merck & Co's Keytruda could catch BMS' rival with new lung c...

Merck & Co's Keytruda blockbuster immunotherapy could have yet another use, after it significantly boosted survival in patients with untreated squamous non-small cell lu

News